Elena Shagisultanova

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 8

Top Venues

NPJ breast cancer

JCO precision oncology

International journal of breast cancer

Clinical cancer research : an official journal of the American Association for Cancer Research

University of Colorado Denver

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Colorado Denver

United States

assistant professor, medical oncology :: Medicine

Publications

Anthony D Elias, Nicole S Spoelstra, Alyse W Staley, Sharon Sams, Lyndsey S Crump, Gregory A Vidal, Virginia F Borges, Peter Kabos, Jennifer R Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Angelo D'Alessandro, Kathryn L Zolman, Adrie van Bokhoven, Yonghua Zhuang, Rosa I Gallagher, Julia D Wulfkuhle, Emanuel F Petricoin Iii, Dexiang Gao, Jennifer K Richer
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer. NPJ breast cancer 9 (1) (2023)
Anthony D Elias, Nicole S Spoelstra, Alyse W Staley, Sharon Sams, Lyndsey S Crump, Gregory A Vidal, Virginia F Borges, Peter Kabos, Jennifer R Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Angelo D'Alessandro, Kathryn L Zolman, Adrie van Bokhoven, Yonghua Zhuang, Rosa I Gallagher, Julia D Wulfkuhle, Emanuel F Petricoin Iii, Dexiang Gao, Jennifer K Richer
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer. NPJ breast cancer 9 (1) (2023)
Anthony D Elias, Nicole S Spoelstra, Alyse W Staley, Sharon Sams, Lyndsey S Crump, Gregory A Vidal, Virginia F Borges, Peter Kabos, Jennifer R Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Angelo D'Alessandro, Kathryn L Zolman, Adrie van Bokhoven, Yonghua Zhuang, Rosa I Gallagher, Julia D Wulfkuhle, Emanuel F Petricoin Iii, Dexiang Gao, Jennifer K Richer
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer. NPJ breast cancer 9 (1) (2023)
Elena Shagisultanova, William J Gradishar, Ursa Brown-Glabberman, Pavani Chalasani, Andrew J Brenner, Alison T Stopeck, Hannah Parris, Dexiang Gao, Tessa Mcspadden, Jose Mayordomo, Jennifer R Diamond, Peter Kabos, Virginia F Borges
Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Aryana R Rasti, Amy Guimaraes-Young, Farrah Datko, Virginia F Borges, Dara L Aisner, Elena Shagisultanova
PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. JCO precision oncology 6 (2022)
Elena Shagisultanova, Lyndsey S Crump, Michelle Borakove, Jessica K Hall, Aryana R Rasti, Benjamin A Harrison, Peter Kabos, Traci R Lyons, Virginia F Borges
Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. Molecular cancer therapeutics (2021)
Vladislav Korobeynikov, Michelle Borakove, Yayi Feng, William M Wuest, Alex B Koval, Anna S Nikonova, Ilya Serebriiskii, Jonathan Chernoff, Virginia F Borges, Erica A Golemis, Elena Shagisultanova
Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer. Breast cancer research and treatment 177 (2) (2019)
Troy B Schedin, Virginia F Borges, Elena Shagisultanova
Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition. International journal of breast cancer 2018 (2018)

Elena Shagisultanova.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Elena Shagisultanova